The European guidelines recommend that 1p/19q status is evaluated to support a diagnosis of oligodendroglioma, IDH mutant and 1p/19q codeleted, and for prognosis, and that treatment decisions are based on the 1p/19q status [10, 11, 12]. The gene discussed is IDH2; the disease is oligodendroglioma.